Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Immunovant, Inc. (IMVT) had Return on Equity of -19.82% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-120.61M |
|
-- |
|
-- |
|
$127.22M |
|
$-127.22M |
|
$7.52M |
|
$-119.70M |
|
$-119.70M |
|
$-120.61M |
|
$-120.61M |
|
$-120.61M |
|
$-120.61M |
|
$-127.22M |
|
$-127.12M |
|
170.87M |
|
170.87M |
|
$-0.71 |
|
$-0.71 |
|
| Balance Sheet Financials | |
$651.76M |
|
$0.74M |
|
$9.68M |
|
$661.44M |
|
$52.90M |
|
-- |
|
-- |
|
$52.90M |
|
$608.54M |
|
$608.54M |
|
$608.54M |
|
171.07M |
|
| Cash Flow Statement Financials | |
$-117.41M |
|
-- |
|
$2.92M |
|
$713.97M |
|
$598.91M |
|
$-115.06M |
|
$18.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-117.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-19.82% |
-19.82% |
|
-18.23% |
|
-19.82% |
|
$3.56 |
|
$-0.69 |
|
$-0.69 |
|